+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetes Drug Market Global & Forecast By Disease, Oral Therapy, Injection, Insulin, Regions, Company

  • ID: 4912084
  • Report
  • January 2020
  • Region: Global
  • 276 Pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now
Diabetes Drug Market is Anticipated to Reach US$ 78.10 Billion by the End of the Year 2026

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly
  • Johnson & Johnson
  • Merck & Co
  • Novo Nordisk
  • MORE

Diabetes drugs are medications that have been prescribed to treat specific diabetes forms such as Type 1 and Type 2 diabetes. Diabetes medicines are used to treat diabetes mellitus to stabilize blood glucose levels through various drugs such as Insulin, Metformin, and Sulphonylureas. The global diabetes drug market is continuously growing at a rapid pace due to the growing prevalence of diabetes all over the world.

The major key drivers of the diabetes drug market are; a growing aging population, increasing sales of novel drugs, rising prevalence of type 2 diabetes and technological advancements, etc. According to the publisher Diabetes Drug Market is anticipated to reach US$ 78.10 Billion by the end of the year 2026.
 
The other market growth factor for diabetes drugs are; approvals of various new drugs such as Canagliflozin, Dapagliflozin, etc., for the treatment of diabetes, which would build several opportunities for the new upcoming as well as existing players in the global diabetes drugs market. The growing adoption rate of diabetes drugs in developing regions such as Asia Pacific like India, China, and Japan and Europe, Spain, France, the UK, and Germany are the important key factors, which would be driving the growth of global diabetes drugs market in upcoming years. According to our research, patient compliance is also one of the important factors in the future growth of diabetes drugs, devices, and monitoring systems used to treat diabetes.

Around the world, various governments’ initiatives to control diabetes disease in a developed and developing nation will further propel the diabetes drug market. Moreover, the high manufacturing cost of drugs, low awareness among people about diabetes treatment and insulin devices are projected to create restrictive to the growth of the diabetes drugs market.

Small and well-established players have as future collaboration, expansion, acquisition, partnership, and new product launch to increase competitive benefits in this market and to uphold the market position in the future. The manufacturers are continually improving their strategy to analyze and update the new product and launching a new solution to meet the changing needs of both patients and health care professionals, which accelerate the global diabetes drug market.

Some of the drugs used to treat type 2 diabetes are Metformin, Actos, Avandia, Lantus subcutaneous, and Invokana. All drugs are administered orally except insulin, Exenatide, Liraglutide, and Pramlintide. Insulin is delivered through insulin delivery devices including infusion pump, intravenous sets, insulin syringe, insulin pen, and jet injectors. Long-acting, intermediate-acting, short-acting, and rapid-acting are some of the types of insulin used to treat diabetes.

The report provides the complete analysis of global diabetes drugs market.

By Disease Type - Type2 Disease holds the Significant Share in the Global Diabetes Drug Market
In this report, we provide full studies of type 1 & type 2 diabetes drugs market. A type 2 diabetes drug holds significant market in the global diabetes drugs market and is anticipated to dominate the market over projection years.

By Therapy - Insulin Therapy dominates the Overall Therapy Market
In this report, we have done complete insight on global diabetes drug market and we have categorized it into three segments and sub-segments on the basis of therapy.

  • Oral
    • (DPP) IV inhibitor
    • SGLT-2
    • Alpha Glucosidase Inhibitor
    • Biguanide
    • Others Oral Drug
  • Injection
    • Glucagon-like peptide (GLP) 1 agonist
    • Amylin receptor against
  • Insulin
    • Rapid – Acting Insulin
    • Long Acting Insulin
    • Premixed Insulin
    • Other Insulin

By Region Type1 Diabetes - United States holds the Significant Market Shares in the Global Diabetes Drug Market
In this report, we provide complete analysis of market share for four major regions such as the United States, 5European Union, Japan and Canada. The United States holds the significant market shares in the global diabetes drugs market.

By Region Type2 Diabetes - United States Dominates Type2 Diabetes Market in Overall Global Diabetes Drugs Market
In this report, we have done complete analysis of type2 diabetes drugs by region; United States, 5European Union, Japan and Canada, China, India, and Brazil. The United States is dominates type2 diabetes market in the global diabetes drug market.

All the companies have been studied from two points

  • Recent Developments
  • Sales Analysis

Company Analysis

  • Novo Nordisk
  • Merck & Co
  • Eli Lilly
  • AstraZeneca
  • Johnson & Johnson

By Disease Type - Global Diabetes Drug Market

  • Type1 Diabetes
  • Type2 Diabetes

By Region - Global Type 1 & Type 2 Diabetes Drug Market, Population

  • United States
  • 5 European Union
  • Japan
  • China
  • India
  • Brazil
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly
  • Johnson & Johnson
  • Merck & Co
  • Novo Nordisk
  • MORE
1. Introductions

2. Research & Methodology

3. Executive Summary

4. Global Diabetes Drug Market

5. Market Share - Global Diabetes Drug
5.1 By Disease Type
5.2 By Therapy – (Oral, Injection, Insulin)
5.3 By Oral Drug
5.4 By Injection Drug
5.5 By Insulin
5.6 By Regions – Type 1 Diabetes Drug
5.7 By Regions – Type 2 Diabetes Drug

6. Disease Type – Global Diabetes Drug Market
6.1 Type 1 Diabetes Drug Market
6.2 Type 2 Diabetes Drug Market

7. Global Diabetes Drug Market by Therapy
7.1 Oral
7.1.1 (DPP) IV inhibitor
7.1.2 SGLT-2
7.1.3 Alpha Glucosidase Inhibitor
7.1.4 Biguanide
7.1.5 Others Oral Drug
7.2 Injection
7.2.1 Glucagon-like peptide (GLP) 1 agonist
7.2.2 Amylin receptor against
7.3 Insulin
7.3.1 Rapid – Acting Insulin
7.3.2 Long Acting Insulin
7.3.3 Premixed Insulin
7.3.4 Other Insulin

8. Global Type 1 Diabetes Drug Market by Region
8.1 United States
8.2 5 European Union
8.3 Japan
8.4 Canada

9. Global Type 2 Diabetes Drug Market by Region
9.1 United States
9.2 5 European Union
9.3 Japan
9.4 China
9.5 India
9.6 Brazil

10. Global Type1 & Type 2 Diabetes Population Market by Region
10.1 United States Diabetes Population
10.1.1 Type1 Diabetes Population
10.1.2 Type 2 Diabetes Population
10.2 5European Union Diabetes Population
10.2.1 Type1 Diabetes Population
10.2.2 Type 2 Diabetes Population
10.3 Japan Diabetes Population
10.3.1 Type1 Diabetes Population
10.3.2 Type 2 Diabetes Population
10.4 Canada Diabetes Population
10.4.1 Type1 Diabetes Population
10.4.2 Type 2 Diabetes Population
10.5 China Diabetes Population
10.5.1 Type1 Diabetes Population
10.5.2 Type 2 Diabetes Population
10.6 India Diabetes Population
10.6.1 Type1 Diabetes Population
10.6.2 Type 2 Diabetes Population
10.7 Brazil Diabetes Population
10.7.1 Type1 Diabetes Population
10.7.2 Type 2 Diabetes Population

11. Merger & acquisitions

12. Market Dynamics
12.1 Growth Driver
12.1.1 The rising prevalence of Diabetes
12.1.2 The Rising Cost of Diabetes Care
12.2 Challenges
12.2.1 Diabetic Ketoacidosis
12.2.2 Severe Hypoglycemia
12.2.3 Weight Gain
12.3 Opportunities

13. Key Players Analysis
13.1 Novo Nordisk
13.1.1 Overview
13.1.2 R&D Pipeline
13.1.3 Sales Analysis
13.2 Merck & Co
13.2.1 Overview
13.2.2 R&D Pipeline
13.2.3 Sales Analysis
13.3 Eli Lilly
13.3.1 Overview
13.3.2 R&D Pipeline
13.3.3 Sales Analysis
13.4 AstraZeneca
13.4.1 Overview
13.4.2 R&D Pipeline
13.4.3 Sales Analysis
13.5 Johnson & Johnson
13.5.1 Overview
13.5.2 R&D Pipeline
13.5.3 Sales Analysis
13.6 Boehringer Ingelheim
13.6.1 Overview
13.6.2 R&D Pipeline
13.6.3 Sales Analysis
13.7 Others

List of Figures:

Figure-01: Global – Diabetes Drugs Market size (Million US$), 2020 & 2026
Figure-02: Global – Diabetes Drugs Growing Segments
Figure-03: Global – Diabetes Drugs Market (Million US$), 2016 – 2019
Figure-04: Global – Forecast for Diabetes Drugs Market(Million US$), 2020 – 2026
Figure-05: Global – Diabetes Drugs Market Share by Disease type (Percent), 2016 – 2019
Figure-06: Global – Forecast for Diabetes Drugs Market Share by disease type(Percent), 2020 – 2026
Figure-07: Global – Diabetes Drugs Market Share by Therapy (Percent), 2016 – 2019
Figure-08: Global – Forecast for Diabetes Drugs Market Share by Therapy (Percent), 2020 – 2026
Figure-09: Global – Diabetes Drugs Market Share by Insulin (Percent), 2016 – 2019
Figure-10: Global – Forecast for Diabetes Drugs Market Share by Insulin (Percent), 2020 – 2026
Figure-11: Global – Type1 Diabetes Drug Market Share by Regions (Percent), 2016 – 2019
Figure-12: Global – Forecast for Type1 Diabetes Drug Market Share by Regions (Percent), 2020 – 2026
Figure-13: Global – Type1 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-14: Global – Forecast for Type1 Diabetes Drugs Market (Million US$), 2020 – 2026
Figure-15: Global – Type2 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-16: Global – Forecast for Type2 Diabetes Drug Market (Million US$), 2020 – 2026
Figure-17: Global – Oral (DPP) IV Inhibitor Drug Market (Million US$), 2016 – 2019
Figure-18: Global – Forecast for Oral (DPP) IV Inhibitor Drug Market (Million US$), 2020 – 2026
Figure-19: Global – Oral SGLT-2 Drug Market (Million US$), 2016 – 2019
Figure-20: Global – Forecast for Oral SGLT-2 Drug Market (Million US$), 2020 – 2026
Figure-21: Global – Oral Alpha Glucosidase Inhibitor Drug Market (Million US$), 2016 – 2019
Figure-22: Global – Forecast for Oral Alpha Glucosidase Inhibitor Drug Market (Million US$), 2020 – 2026
Figure-23: Global – Oral Biguanide Drug Market (Million US$), 2016 – 2019
Figure-24: Global – Forecast for Oral Biguanide Drug Market (Million US$), 2020 – 2026
Figure-25: Global – Oral Others Drug Market (Million US$), 2016 – 2019
Figure-26: Global – Forecast for Oral Others Drug Market (Million US$), 2020 – 2026
Figure-27: Global – Diabetes Injectable Drug Glucagon-like peptide (GLP) 1 Agonist Market (Million US$), 2016 – 2019
Figure-28: Global – Forecast for Diabetes Injectable Drug Glucagon-like peptide (GLP) 1 agonist Market (Million US$), 2020 – 2026
Figure-29: Global – Diabetes Injectable Drug Amylin receptor agonist Market (Million US$), 2016 – 2019
Figure-30: Global – Forecast for Diabetes Injectable Drug Amylin receptor agonist Market (Million US$), 2020 – 2026
Figure-31: Global – Diabetes Insulin Drug Rapid Acting (Fast Acting) Market (Million US$), 2016 – 2019
Figure-32: Global – Forecast for Diabetes Insulin Drug Rapid Acting (Fast Acting) Market (Million US$), 2020 – 2026
Figure-33: Global – Diabetes Insulin Drug Long Acting Market (Million US$), 2016 – 2019
Figure-34: Global – Forecast for Diabetes Insulin Drug Long Acting Market (Million US$), 2020 – 2026
Figure-35: Global – Diabetes Insulin Drug Premixed Market (Million US$), 2016 – 2019
Figure-36: Global – Forecast for Diabetes Insulin Drug Premixed Market (Million US$), 2020 – 2026
Figure-37: Global – Diabetes Drug Other Insulin (Including Human Insulin) Market (Million US$), 2016 – 2019
Figure-38: Global – Forecast for Diabetes Drug Other Insulin (Including Human Insulin) Market (Million US$), 2020 – 2026
Figure-39: United States – Type1 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-40: United States – Forecast for Type1 Diabetes Drug Market (Million US$), 2020 – 2026
Figure-41: 5 European Union – Type 1 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-42: 5 European Union – Forecast for type 1 Diabetes Drug Market (Million US$), 2020 – 2026
Figure-43: Japan – Type1 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-44: Japan – Forecast for Type1 Diabetes Drug Market (Million US$), 2020 – 2026
Figure-45: Canada – Type 1 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-46: Canada – Forecast for Type1 Diabetes Drug Market (Million US$), 2020 – 2026
Figure-47: United States – Type2 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-48: United States – Forecast for Type2 Diabetes Drug Market (Million US$), 2020 – 2026
Figure-49: 5 European Union – Type2 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-50: 5 European Union – Forecast for Type2 Diabetes Drug Market (Million US$), 2020 – 2026
Figure-51: Japan – Type2 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-52: Japan – Forecast for Type2 Diabetes Drug Market (Million US$), 2020 – 2026
Figure-53: China – Type2 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-54: China – Forecast for Type2 Diabetes Drug Market (Million US$), 2020 – 2026
Figure-55: India – Type2 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-56: India – Forecast for Type2 Diabetes Drug Market (Million US$), 2020 – 2026
Figure-57: Brazil – Type2 Diabetes Drug Market (Million US$), 2016 – 2019
Figure-58: Brazil – Forecast for Type2 Diabetes Drug Market (Million US$), 2020 – 2026
Figure-59: United States – Diabetes Population (Thousands), 2015 – 2019
Figure-60: United States – Forecast for Diabetes Population (Thousands), 2020 – 2026
Figure-61: United States – Type1 Diabetes Population (Thousands), 2015 – 2019
Figure-62: United States – Forecast for Type1 Diabetes Population (Thousands), 2020 – 2026
Figure-63: United States – Type2 Diabetes Population (Thousands), 2015 – 2019
Figure-64: United States – Forecast for Type2 Diabetes Population (Thousands), 2020 – 2026
Figure-65: 5European Union – Diabetes Population (Thousands), 2015 – 2019
Figure-66: 5European Union – Forecast for Diabetes Population (Thousands), 2020 – 2026
Figure-67: 5 European Union – Type1 Diabetes Population (Thousands), 2015 – 2019
Figure-68: 5 European Union – Forecast for Type1 Diabetes Population (Thousands), 2020 – 2026
Figure-69: 5European Union – Type2 Diabetes Population (Thousands), 2015 – 2019
Figure-70: 5European Union – Forecast for Type2 Diabetes Population (Thousands), 2020 – 2026
Figure-71: Japan – Diabetes Population (Thousands), 2015 – 2019
Figure-72: Japan – Forecast for Diabetes Population (Thousands), 2020 – 2026
Figure-73: Japan – Type1 Diabetes Population (Thousands), 2015 – 2019
Figure-74: Japan – Forecast for Type1 Diabetes Population (Thousands), 2020 – 2026
Figure-75: Japan – Type2 Diabetes Population (Thousands), 2015 – 2019
Figure-76: Japan – Forecast for Type2 Diabetes Population (Thousands), 2020 – 2026
Figure-77: Canada – Diabetes Population (Thousands), 2015 – 2019
Figure-78: Canada – Forecast for Diabetes Population (Thousands), 2020 – 2026
Figure-79: Canada – Type1 Diabetes Population (Thousands), 2015 – 2019
Figure-80: Canada – Forecast for Type1 Diabetes Population (Thousands), 2020 – 2026
Figure-81: Canada – Type2 Diabetes Population (Thousands), 2015 – 2019
Figure-82: Canada – Forecast for Type2 Diabetes Population (Thousands), 2020 – 2026
Figure-83: China – Diabetes Population (Thousands), 2015 – 2019
Figure-84: China – Forecast for Diabetes Population (Thousands), 2020 – 2026
Figure-85: China – Type1 Diabetes Population (Thousands), 2015 – 2019
Figure-86: China – Forecast for Type1 Diabetes Population (Thousands), 2020 – 2026
Figure-87: China – Type2 Diabetes Population (Thousands), 2015 – 2019
Figure-88: China – Forecast for type2 Diabetes Population (Thousands), 2020 – 2026
Figure-89: India – Diabetes Population (Thousands), 2015 – 2019
Figure-90: India – Forecast for type2 Diabetes Population (Thousands), 2020 – 2026
Figure-91: India – Type1 Diabetes Population (Thousands), 2015 – 2019
Figure-92: India – Forecast for Type1 Diabetes Population (Thousands), 2020 – 2026
Figure-93: India – Type2 Diabetes Population (Thousands), 2015 – 2019
Figure-94: India – Forecast for Type2 Diabetes Population (Thousands), 2020 – 2026
Figure-95: Brazil – Diabetes Population (Thousands), 2015 – 2019
Figure-96: Brazil – Forecast for Diabetes Population (Thousands), 2020 – 2026
Figure-97: Brazil – Diabetes Population (Thousands), 2015 – 2019
Figure-98: Brazil – Forecast for Diabetes Population (Thousands), 2020 – 2026
Figure-99: Brazil – Diabetes Population (Thousands), 2015 – 2019
Figure-100: Brazil – Forecast for Diabetes Population (Thousands), 2020 – 2026
Figure-101: Global – Novo Nordisk Diabetes Drug Sales (Million US$), 2016 – 2019
Figure-102: Global – Forecast for Novo Nordisk Diabetes Drug Sales (Million US$), 2020 – 2026
Figure-103: Global – Merck & Co Diabetes Drug Sales (Million US$), 2016 – 2019
Figure-104: Global – Forecast for Merck & Co Diabetes Drug Sales (Million US$), 2020 – 2026
Figure-105: Global – Eli Lilly Diabetes Drug Sales (Million US$), 2016 – 2019
Figure-106: Global – Forecast for Eli Lilly Diabetes Drug Sales (Million US$), 2020 – 2026
Figure-108: Global – AstraZeneca Diabetes Drug Sales (Million US$), 2016 – 2019
Figure-109: Global – Forecast for AstraZeneca Diabetes Drug Sales (Million US$), 2020 – 2026
Figure-110: Global – Johnson & Johnson Diabetes Drug Sales (Million US$), 2015 – 2018
Figure-111: Global – Boehringer Ingelheim Diabetes Drug Sales (Million US$), 2015 – 2019
Figure-112: Global – Forecast for Boehringer Ingelheim Diabetes Drug Sales (Million US$), 2020 – 2026

List of Table:

Table-1: Global – Diabetes Drugs Market Share by Oral Drug (Percent), 2016 – 2019
Table-2: Global – Forecast for Diabetes Drugs Market Share by Oral Drug (Percent), 2020 – 2026
Table-3: Global – Diabetes Drugs Market Share by Injectable Drug (Percent), 2016 – 2019
Table-4: Global – Forecast for Diabetes Drugs Market Share by Injectable Drug (Percent), 2020 – 2026
Table-5: Global – Type2 Diabetes Drug Market Share by Regions (Percent), 2016 – 2019
Table-6: Global – Forecast for Type2 Diabetes Drug Market Share by Regions (Percent), 2020 – 2026
Table-7: Number of people with diabetes worldwide and per region in 2017 and 2045 (20-79 years)
Table-8: Top Therapeutic Classes By Invoice Spending

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Novo Nordisk
  • Merck & Co
  • Eli Lilly
  • AstraZeneca
  • Johnson & Johnson
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll